167 related articles for article (PubMed ID: 37306288)
1. Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study.
Gashaw I; Reif S; Wiesinger H; Kaiser A; Zollmann FS; Scheerans C; Grevel J; Piraino P; Seidel H; Peters M; Rottmann A; Rohde B; Arlt W; Hilpert J
Eur J Endocrinol; 2023 Jul; 188(7):578-591. PubMed ID: 37306288
[TBL] [Abstract][Full Text] [Related]
2. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
Byrns MC; Duan L; Lee SH; Blair IA; Penning TM
J Steroid Biochem Mol Biol; 2010 Feb; 118(3):177-87. PubMed ID: 20036328
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
Byrns MC; Mindnich R; Duan L; Penning TM
J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
[TBL] [Abstract][Full Text] [Related]
4. 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer.
Barnard M; Quanson JL; Mostaghel E; Pretorius E; Snoep JL; Storbeck KH
J Steroid Biochem Mol Biol; 2018 Oct; 183():192-201. PubMed ID: 29936123
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
Himura R; Kawano S; Nagata Y; Kawai M; Ota A; Kudo Y; Yoshino Y; Fujimoto N; Miyamoto H; Endo S; Ikari A
Chem Biol Interact; 2024 Jan; 388():110840. PubMed ID: 38122923
[TBL] [Abstract][Full Text] [Related]
6. Aldo-keto reductase 1C3-Assessment as a new target for the treatment of endometriosis.
Rižner TL; Penning TM
Pharmacol Res; 2020 Feb; 152():104446. PubMed ID: 31546014
[TBL] [Abstract][Full Text] [Related]
7. Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis.
Hevir N; Vouk K; Sinkovec J; Ribič-Pucelj M; Rižner TL
Chem Biol Interact; 2011 May; 191(1-3):217-26. PubMed ID: 21232532
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the major single nucleotide polymorphic variants of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase).
Detlefsen AJ; Wangtrakuldee P; Penning TM
J Steroid Biochem Mol Biol; 2022 Jul; 221():106121. PubMed ID: 35489629
[TBL] [Abstract][Full Text] [Related]
9. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
[TBL] [Abstract][Full Text] [Related]
10. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Byrns MC; Steckelbroeck S; Penning TM
Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis.
Hilpert J; Groettrup-Wolfers E; Kosturski H; Bennett L; Barnes CLK; Gude K; Gashaw I; Reif S; Steger-Hartmann T; Scheerans C; Solms A; Rottmann A; Mao G; Chapron C
Drugs R D; 2023 Sep; 23(3):221-237. PubMed ID: 37422772
[TBL] [Abstract][Full Text] [Related]
12. Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Chang TS; Lin HK; Rogers KA; Brame LS; Yeh MM; Yang Q; Fung KM
Int J Clin Exp Pathol; 2013; 6(11):2419-29. PubMed ID: 24228104
[TBL] [Abstract][Full Text] [Related]
13. Human dehydrogenase/reductase SDR family member 11 (DHRS11) and aldo-keto reductase 1C isoforms in comparison: Substrate and reaction specificity in the reduction of 11-keto-C
Endo S; Morikawa Y; Kudo Y; Suenami K; Matsunaga T; Ikari A; Hara A
J Steroid Biochem Mol Biol; 2020 May; 199():105586. PubMed ID: 31926269
[TBL] [Abstract][Full Text] [Related]
14. AKR1C3-Mediated Adipose Androgen Generation Drives Lipotoxicity in Women With Polycystic Ovary Syndrome.
O'Reilly MW; Kempegowda P; Walsh M; Taylor AE; Manolopoulos KN; Allwood JW; Semple RK; Hebenstreit D; Dunn WB; Tomlinson JW; Arlt W
J Clin Endocrinol Metab; 2017 Sep; 102(9):3327-3339. PubMed ID: 28645211
[TBL] [Abstract][Full Text] [Related]
15. Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
Pippione AC; Carnovale IM; Bonanni D; Sini M; Goyal P; Marini E; Pors K; Adinolfi S; Zonari D; Festuccia C; Wahlgren WY; Friemann R; Bagnati R; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2018 Apr; 150():930-945. PubMed ID: 29602039
[TBL] [Abstract][Full Text] [Related]
16. Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells.
Tian Y; Zhao L; Wang Y; Zhang H; Xu D; Zhao X; Li Y; Li J
Asian J Androl; 2016; 18(4):607-12. PubMed ID: 26698234
[TBL] [Abstract][Full Text] [Related]
17. Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Miller VL; Lin HK; Murugan P; Fan M; Penning TM; Brame LS; Yang Q; Fung KM
Int J Clin Exp Pathol; 2012; 5(4):278-89. PubMed ID: 22670171
[TBL] [Abstract][Full Text] [Related]
18. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
[TBL] [Abstract][Full Text] [Related]
19. Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
Mantel A; Carpenter-Mendini A; VanBuskirk J; Pentland AP
Exp Dermatol; 2014 Aug; 23(8):573-8. PubMed ID: 24917395
[TBL] [Abstract][Full Text] [Related]
20. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
